Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+3.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — maintain Nasdaq listing and avoid delisting notices: Delisting notice received vs no notice target.
Jasper is cutting losses fast. Operating loss fell from $27M to $11M. Net loss dropped from $27M to $1M. The company aims to stabilize finances soon.
Jasper still loses money with no revenue. Nasdaq delisting risk is real. Key board members left recently. These hurt confidence and financial health.
The market is selling off sharply on risks like delisting and losses. No clear consensus or fair value is available. Our view sees some progress but high risk remains.
Breaks if: net loss stays above -$1.17M by 2026-Q1
Breaks if: operating loss stays above -$11M by 2026-Q1
receipt of a delisting notice or failure to meet listing rules
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. JSPR is in the healthcare sector, focusing on advancing clinical programs while facing significant operational losses and high volatility in management performance.
The market seems to be pricing in ongoing losses and a challenging operational environment. Recent financial performance has been neutral, but the stock has reacted positively, suggesting some optimism about its potential despite the risks.
Management is on track with advancing KP-104 and briquilimab, but the overall financial performance remains mixed due to ongoing R&D expenses. There is a high probability of an earnings miss in the near term, which could impact sentiment.
The long-term thesis depends on the success of clinical trials and regulatory engagements, as well as the performance of sector bellwethers like VRTX and REGN. Any shifts in these companies' earnings could significantly affect JSPR's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, JSPR's trajectory will largely depend on its clinical advancements and the broader healthcare sector's performance. Not investment advice.